First-line Avastin with chemo in breast cancer has 'too many uncertainties' for NICE
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has opened a consultation on new, draft guidance which does not recommend bevacizumab (Roche's Avastin), in combination with capecitabine, for the first-line treatment of metastatic breast cancer. The Institute said there were "too many uncertainties" for it to recommend the drug, and it highlighted the paucity of overall survival data.